Anatara Lifesciences Ltd (ANR) - Total Liabilities

Latest as of June 2025: AU$612.42K AUD ≈ $433.33K USD

Based on the latest financial reports, Anatara Lifesciences Ltd (ANR) has total liabilities worth AU$612.42K AUD (≈ $433.33K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Anatara Lifesciences Ltd - Total Liabilities Trend (2011–2025)

This chart illustrates how Anatara Lifesciences Ltd's total liabilities have evolved over time, based on quarterly financial data. See Anatara Lifesciences Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Anatara Lifesciences Ltd Competitors by Total Liabilities

The table below lists competitors of Anatara Lifesciences Ltd ranked by their total liabilities.

Company Country Total Liabilities
Lambo Group Bhd
KLSE:0018
Malaysia RM17.52 Million
Nortec Minerals Corp
V:NVT
Canada CA$355.71K
Leapfrog Acquisition Corporation Warrants
NASDAQ:LFACW
USA $75.00 Million
Reliance Global Group, Inc.
NASDAQ:EZRA
USA $6.37 Million
Asdion Bhd
KLSE:0068
Malaysia RM18.03 Million
Metronic Global Bhd
KLSE:0043
Malaysia RM41.66 Million
Reinhold Europe AB
WAR:RHD
Poland zł2.15 Million
Grupo Vasconia S.A.B
MX:VASCONI
Mexico MX$2.18 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down Anatara Lifesciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Anatara Lifesciences Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.89 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.14 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.53 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Anatara Lifesciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Anatara Lifesciences Ltd (2011–2025)

The table below shows the annual total liabilities of Anatara Lifesciences Ltd from 2011 to 2025.

Year Total Liabilities Change
2025-06-30 AU$612.42K
≈ $433.33K
+99.58%
2024-06-30 AU$306.85K
≈ $217.12K
-37.99%
2023-06-30 AU$494.83K
≈ $350.13K
+22.68%
2022-06-30 AU$403.35K
≈ $285.40K
-18.79%
2021-06-30 AU$496.67K
≈ $351.43K
+1.99%
2020-06-30 AU$486.96K
≈ $344.56K
+4.33%
2019-06-30 AU$466.76K
≈ $330.26K
-61.90%
2018-06-30 AU$1.22 Million
≈ $866.73K
+314.62%
2017-06-30 AU$295.44K
≈ $209.04K
-33.55%
2016-06-30 AU$444.62K
≈ $314.60K
+202.51%
2015-06-30 AU$146.98K
≈ $104.00K
-35.43%
2014-06-30 AU$227.62K
≈ $161.05K
-35.51%
2013-06-30 AU$352.96K
≈ $249.74K
+141.75%
2012-06-30 AU$146.00K
≈ $103.30K
+630.00%
2011-06-30 AU$20.00K
≈ $14.15K
--

About Anatara Lifesciences Ltd

AU:ANR Australia Biotechnology
Market Cap
$1.92 Million
AU$2.72 Million AUD
Market Cap Rank
#29994 Global
#1763 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$1.64
About

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more